Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond-Reference-Cited by-同舟云学术

Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond

Published:2015-03-11 Issue:4 Volume:35 Page:720-752
ISSN:0198-6325
Container-title:Medicinal Research Reviews
language:en
Short-container-title:Med. Res. Rev.

Author:

Wei Manman¹,Wang Xiang²,Song Zilan¹,Jiao Mingkun¹,Ding Jian²,Meng Ling-Hua²,Zhang Ao¹

Affiliation:

1. CAS Key Laboratory of Receptor Research, Synthetic Organic & Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM); Chinese Academy of Sciences; Shanghai 201203 China

2. Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM); Chinese Academy of Sciences; Shanghai 201203 China

Publisher

Wiley

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Reference94 articles.

1. Cancer Facts & Figures 2013 American Cancer Society

2. Improved survival in chronic lymphocytic leukemia in the past decade: A population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden;Kristinsson;Haematologia,2009

3. Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network;Smith;Br J Cancer,2011

4. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients;Molica;Leuk Lymphoma,2006

5. Mechanisms of disease: Chronic lymphocytic leukemia;Chiorazzi;N Eng J Med,2005

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon;Neoplasia;2024-11

2. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer;Cell Death & Disease;2024-07-03

3. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas;Life Sciences;2024-06

4. The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment;Frontiers in Pharmacology;2024-04-16

5. Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia;Journal of Medicinal Chemistry;2024-04-05